Home Visit
Upload
.png)
EGFR Mutation Test
50+ booked in last 3 days
No special precautions
Sample Type
Blood
Recommended for
Male, Female
Report
Within 24 Hours
Blood test at Home
NABL & CAP Accredited Labs
Accurate & Quality Test Reports
Trusted by Leading Doctors & Hospitals
EGFR Mutation Test Overview
Epidermal growth factor receptor (EGFR) mutation analysis detects EGFR gene mutations in tumor specimens of patients with nonsmall
cell lung cancer (NSCLC). EGFR, when activated due to mutation, plays a role in cellular tumor growth and proliferation and is the target of
tyrosine kinase inhibitors (TKI).
Up to 20% of NSCLC tumors harbour the EGFR mutation in Exons 18-21, and that ~85% of patients with these patients respond to TKI treatment
Summary Price Of EGFR Mutation Test
We are a trusted lab, offering EGFR Mutation Test with a transparent pricing structure.
The cost of EGFR Mutation Test in India varies as per the city in India.
The average price of EGFR Mutation Test ranges from ₹8000 to ₹9900.
The price for the test in the following cities is:
- Chennai: ₹8,000
- Delhi: ₹8,000
- Mumbai: ₹8,000
- Pune: ₹8,000
Contact Metropolis to book an appointment online.
Frequently Asked Questions
EGFR Mutation test is done to detect mutations in EGFR gene in exons 18 to 21. Patients with mutations respond well to TKI treatment
EGFR Mutation test detects mutations in EGFR gene with real time PCR
Sample is provided by the recommending doctor. Tumor containing FFPE block (>10% of tumor). Tumor containing tissue fixed in 10% neutral buffered formalin with duration of 6 to 72 hours
Patients with EGFR mutation respond well to TKI treatment. KRAS mutations are associated with intrinsic
Tyrosine Kinase (TKI) resistance. Hence, KRAS codon 12/13 mutation testing would be useful for selection of the patients for TKI therapy.
Patients who are negative for EGFR mutations can additionally be tested for ALK rearrangement and the ALK positive NSCLC cases are likely to benefit from FDA approved crizotinib (XALKORI) therapy
Patients with PD-L1 expression predicts potential response to immunotherapy such as nivolumab and pembrolizumab
Ratings & Reviews (0)
Why Metropolis?
Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.
We offer a comprehensive range of 4000+ clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease.
WhatsApp